{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:40:51Z","timestamp":1789540851665,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,22]],"date-time":"2015-03-22T00:00:00Z","timestamp":1426982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s11920-015-0573-1","type":"journal-article","created":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T07:00:04Z","timestamp":1426921204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Psychopharmacologic Treatment of Eating Disorders: Emerging Findings"],"prefix":"10.1007","volume":"17","author":[{"given":"Susan L.","family":"McElroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna I.","family":"Guerdjikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Paul E.","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,22]]},"reference":[{"key":"573_CR1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"A.P.A.","year":"2013","unstructured":"A.P.A. Diagnostic and Statistical Manual of Mental Disorders. Fifthth ed. Washington, DC: American Psychiatric Association; 2013.","edition":"Fifth"},{"issue":"6","key":"573_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3109\/15622975.2011.602720","volume":"12","author":"M Aigner","year":"2011","unstructured":"Aigner M, Treasure J, Kaye W, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2011;12(6):400\u201343.","journal-title":"World J Biol Psychiatry"},{"issue":"14","key":"573_CR3","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1517\/14656566.2012.721781","volume":"13","author":"SL McElroy","year":"2012","unstructured":"McElroy SL, Guerdjikova AI, Mori N, et al. Current pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Pharmacother. 2012;13(14):2015\u201326.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"573_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/eat.22104","volume":"46","author":"JE Mitchell","year":"2013","unstructured":"Mitchell JE, Roerig J, Steffen K. Biological therapies for eating disorders. Int J Eat Disord. 2013;46(5):470\u20137.","journal-title":"Int J Eat Disord"},{"issue":"1","key":"573_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/14728214.2014.879291","volume":"19","author":"DL Reas","year":"2014","unstructured":"Reas DL, Grilo CM. Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs. 2014;19(1):99\u2013142.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"9","key":"573_CR6","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1177\/1060028013503127","volume":"47","author":"JC Sebaaly","year":"2013","unstructured":"Sebaaly JC, Cox S, Hughes CM, et al. Use of fluoxetine in anorexia nervosa before and after weight restoration. Ann Pharmacother. 2013;47(9):1201\u20135.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"573_CR7","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1017\/S0033291711000390","volume":"41","author":"E Attia","year":"2011","unstructured":"Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41(10):2177\u201382. This small (N\u2009=\u200923) but well designed RCT showed that olanzapine, when given in conjunction with compliance enhancement sessions, was superior to placebo for weight gain but not psychological symptoms in patients with AN.","journal-title":"Psychol Med"},{"issue":"3","key":"573_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/cap.2010.0139","volume":"21","author":"V Kafantaris","year":"2011","unstructured":"Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):207\u201312.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"573_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jaac.2011.06.009","volume":"50","author":"J Hagman","year":"2011","unstructured":"Hagman J, Gralla J, Sigel E, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 2011;50(9):915\u201324. This is the largest (N\u2009=\u200940) RCT to date of an SGA in AN: risperidone was superior to placebo for interpersonal distrust but not for weight gain or other psychological symptoms.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"573_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/erv.2169","volume":"20","author":"PS Powers","year":"2012","unstructured":"Powers PS, Klabunde M, Kaye W. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev. 2012;20(4):331\u20134.","journal-title":"Eur Eat Disord Rev"},{"issue":"1","key":"573_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/eat.22173","volume":"47","author":"A Andries","year":"2014","unstructured":"Andries A, Frystyk J, Flyvbjerg A, et al. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord. 2014;47(1):18\u201323.","journal-title":"Int J Eat Disord"},{"key":"573_CR12","doi-asserted-by":"crossref","unstructured":"Andries A, Gram B, Stoving RK. Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial. Eat Weight Disord. 2014.","DOI":"10.1007\/s40519-014-0132-5"},{"issue":"3","key":"573_CR13","doi-asserted-by":"publisher","first-page":"e90721","DOI":"10.1371\/journal.pone.0090721","volume":"9","author":"YR Kim","year":"2014","unstructured":"Kim YR, Kim CH, Park JH, et al. The impact of intranasal oxytocin on attention to social emotional stimuli in patients with anorexia nervosa: a double blind within-subject cross-over experiment. PLoS ONE. 2014;9(3):e90721.","journal-title":"PLoS ONE"},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.psyneuen.2014.02.019","volume":"44","author":"YR Kim","year":"2014","unstructured":"Kim YR, Kim CH, Cardi V, et al. Intranasal oxytocin attenuates attentional bias for eating and fat shape stimuli in patients with anorexia nervosa. Psychoneuroendocrinology. 2014;44:133\u201342.","journal-title":"Psychoneuroendocrinology"},{"key":"573_CR15","doi-asserted-by":"crossref","unstructured":"Steinglass JE, Kaplan SC, Liu Y et al. The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: a preliminary report. Int J Eat Disord. 2014.","DOI":"10.1002\/eat.22343"},{"issue":"2\u20133","key":"573_CR16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.psychres.2012.07.012","volume":"200","author":"M Bloch","year":"2012","unstructured":"Bloch M, Ish-Shalom S, Greenman Y, et al. Dehydroepiandrosterone treatment effects on weight, bone density, bone metabolism and mood in women suffering from anorexia nervosa-a pilot study. Psychiatry Res. 2012;200(2\u20133):544\u20139.","journal-title":"Psychiatry Res"},{"issue":"8","key":"573_CR17","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.4088\/JCP.13m08365","volume":"74","author":"M Misra","year":"2013","unstructured":"Misra M, Katzman DK, Estella NM, et al. Impact of physiologic estrogen replacement on anxiety symptoms, body shape perception, and eating attitudes in adolescent girls with anorexia nervosa: data from a randomized controlled trial. J Clin Psychiatry. 2013;74(8):e765\u2013771.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"573_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/YIC.0b013e328080ca31","volume":"22","author":"F Brambilla","year":"2007","unstructured":"Brambilla F, Garcia CS, Fassino S, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22(4):197\u2013204.","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"573_CR19","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1176\/appi.ajp.2008.07121900","volume":"165","author":"H Bissada","year":"2008","unstructured":"Bissada H, Tasca GA, Barber AM, et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008;165(10):1281\u20138.","journal-title":"Am J Psychiatry"},{"key":"573_CR20","volume-title":"Eating Disorder Inventory-2: Professional Manual","author":"DM Garner","year":"1991","unstructured":"Garner DM. Eating Disorder Inventory-2: Professional Manual. Odessa: Psychological Assessment Resources; 1991."},{"issue":"6","key":"573_CR21","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.4088\/JCP.12r07691","volume":"73","author":"T Kishi","year":"2012","unstructured":"Kishi T, Kafantaris V, Sunday S, et al. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry. 2012;73(6):e757\u2013766.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"573_CR22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/eat.22059","volume":"46","author":"J Lebow","year":"2013","unstructured":"Lebow J, Sim LA, Erwin PJ, et al. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord. 2013;46(4):332\u20139.","journal-title":"Int J Eat Disord"},{"issue":"1","key":"573_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40337-014-0027-x","volume":"2","author":"J Vos de","year":"2014","unstructured":"de Vos J, Houtzager L, Katsaragaki G, et al. Meta analysis on the efficacy of pharmacotherapy versus placebo on anorexia nervosa. J Eat Disord. 2014;2(1):27.","journal-title":"J Eat Disord"},{"issue":"4","key":"573_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11920-012-0287-6","volume":"14","author":"TD Brewerton","year":"2012","unstructured":"Brewerton TD. Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials. Curr Psychiatry Rep. 2012;14(4):398\u2013405.","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"573_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/eat.20923","volume":"45","author":"J Lock","year":"2012","unstructured":"Lock J, Brandt H, Woodside B, et al. Challenges in conducting a multi-site randomized clinical trial comparing treatments for adolescent anorexia nervosa. Int J Eat Disord. 2012;45(2):202\u201313.","journal-title":"Int J Eat Disord"},{"key":"573_CR26","volume-title":"State-Trait Anxiety Inventory for Children","author":"CD Spielberger","year":"1973","unstructured":"Spielberger CD. State-Trait Anxiety Inventory for Children. Palo Alto: Consulting Psychologist Press; 1973."},{"issue":"4","key":"573_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/1098-108X(198707)6:4<485::AID-EAT2260060405>3.0.CO;2-O","volume":"6","author":"PJ Cooper","year":"1987","unstructured":"Cooper PJ, Taylor MJ, Cooper Z, et al. The development and validation of the body shape questionnaire. Int Eat Disord. 1987;6(4):485\u201394.","journal-title":"Int Eat Disord"},{"issue":"2","key":"573_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.physbeh.2012.02.009","volume":"106","author":"MJ Devlin","year":"2012","unstructured":"Devlin MJ, Kissileff HR, Zimmerli EJ, et al. Gastric emptying and symptoms of bulimia nervosa: effect of a prokinetic agent. Physiol Behav. 2012;106(2):238\u201342.","journal-title":"Physiol Behav"},{"key":"573_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/eat.20946","volume":"45","author":"AI Guerdjikova","year":"2012","unstructured":"Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord. 2012;45:281\u20139.","journal-title":"Int J Eat Disord"},{"issue":"4","key":"573_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4088\/JCP.12m08071","volume":"74","author":"MA White","year":"2013","unstructured":"White MA, Grilo CM. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(4):400\u20136. This is the only RCT of bupropion, an antidepressant contraindicated in AN and BN, in BED. Bupropion was not superior to placebo for decreasing binge eating but was associated with mild weight loss. Importantly, there were no seizures with bupropion.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"573_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.brat.2013.01.002","volume":"51","author":"CM Grilo","year":"2013","unstructured":"Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino\/as. Behav Res Ther. 2013;51(3):167\u201375.","journal-title":"Behav Res Ther"},{"key":"573_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brat.2014.04.002","volume":"58","author":"CM Grilo","year":"2014","unstructured":"Grilo CM, Masheb RM, White MA, et al. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. Behav Res Ther. 2014;58:1\u20139.","journal-title":"Behav Res Ther"},{"issue":"1","key":"573_CR33","first-page":"20","volume":"121","author":"Z Pataky","year":"2013","unstructured":"Pataky Z, Gasteyger C, Ziegler O, et al. Efficacy of rimonabant in obese patients with binge eating disorder. Exp Clin Endocrinol Diabetes. 2013;121(1):20\u20136.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"573_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/eat.22114","volume":"46","author":"SL McElroy","year":"2013","unstructured":"McElroy SL, Guerdjikova AI, Blom TJ, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013;46(3):239\u201345.","journal-title":"Int J Eat Disord"},{"issue":"5\u20136","key":"573_CR35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/FBP.0b013e328357bd62","volume":"23","author":"RL Corwin","year":"2012","unstructured":"Corwin RL, Boan J, Peters KF, et al. Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study. Behav Pharmacol. 2012;23(5\u20136):616\u201325.","journal-title":"Behav Pharmacol"},{"issue":"1","key":"573_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jpsychores.2013.03.092","volume":"75","author":"KA Brownley","year":"2013","unstructured":"Brownley KA, Von Holle A, Hamer RM, et al. A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study. J Psychosom Res. 2013;75(1):36\u201342.","journal-title":"J Psychosom Res"},{"key":"573_CR37","doi-asserted-by":"crossref","unstructured":"McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235\u201346. This is the first RCT of a psychostimulant in BED. It showed that lisdexamfetamine at 50 and 70\u00a0mg\/day, but not 30\u00a0mg\/day, significantly decreased binge eating behavior as compared to placebo in patients with BED.","DOI":"10.1001\/jamapsychiatry.2014.2162"},{"issue":"10","key":"573_CR38","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.biopsych.2005.03.001","volume":"57","author":"CM Grilo","year":"2005","unstructured":"Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2005;57(10):1193\u2013201.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"573_CR39","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/oby.2005.208","volume":"13","author":"A Golay","year":"2005","unstructured":"Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005;13(10):1701\u20138.","journal-title":"Obes Res"},{"issue":"11","key":"573_CR40","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1001\/archpsyc.60.11.1109","volume":"60","author":"JC Appolinario","year":"2003","unstructured":"Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 2003;60(11):1109\u201316.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"573_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF02850181","volume":"22","author":"W Milano","year":"2005","unstructured":"Milano W, Petrella C, Casella A, et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther. 2005;22(1):25\u201331.","journal-title":"Adv Ther"},{"issue":"1","key":"573_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1176\/appi.ajp.2007.06121970","volume":"165","author":"DE Wilfley","year":"2008","unstructured":"Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 2008;165(1):51\u20138.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"573_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0306-4603(82)90024-7","volume":"7","author":"J Gormally","year":"1982","unstructured":"Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among obese persons. Addict Behav. 1982;7(1):47\u201355.","journal-title":"Addict Behav"},{"issue":"1","key":"573_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0022-3999(85)90010-8","volume":"29","author":"AJ Stunkard","year":"1985","unstructured":"Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71\u201383.","journal-title":"J Psychosom Res"},{"issue":"2","key":"573_CR45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/eat.20802","volume":"44","author":"RD Barnes","year":"2011","unstructured":"Barnes RD, Masheb RM, White MA, et al. Comparison of methods for identifying and assessing obese patients with binge eating disorder in primary care settings. Int J Eat Disord. 2011;44(2):157\u201363.","journal-title":"Int J Eat Disord"},{"key":"573_CR46","unstructured":"Alho H, Lahti T, Appelberg B et al. Opioid antagonist naloxone nasal spray treatment for patients with binge eating disorder: a randomized controlled trial (Poster # NR4-29). Presented at American Psychiatric Association 166th Annual Meeting; May 18\u201322; San Francisco, CA 2013."},{"key":"573_CR47","unstructured":"McElroy SL, Hudson J, Ferreira-Cornwell MC et al. Randomized controlled safety and efficacy trials of lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder (Poster # NR8-054). Presented at the American Psychiatric Association 167th Annual Meeting; May 3\u20137; New York, NY 2014."},{"issue":"3","key":"573_CR48","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4088\/JCP.v68n0306","volume":"68","author":"SL McElroy","year":"2007","unstructured":"McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007;68(3):390\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"573_CR49","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1176\/ajp.2006.163.5.893","volume":"163","author":"JP O\u2019Reardon","year":"2006","unstructured":"O\u2019Reardon JP, Allison KC, Martino NS, et al. A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry. 2006;163(5):893\u20138.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"573_CR50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/JCP.0b013e318254239b","volume":"32","author":"JS Vander Wal","year":"2012","unstructured":"Vander Wal JS, Gang CH, Griffing GT, et al. Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(3):341\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"573_CR51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1468-1331.2005.01017.x","volume":"12","author":"F Provini","year":"2005","unstructured":"Provini F, Albani F, Vetrugno R, et al. A pilot double-blind placebo-controlled trial of low-dose pramipexole in sleep-related eating disorder. Eur J Neurol. 2005;12(6):432\u20136.","journal-title":"Eur J Neurol"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-015-0573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-015-0573-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-015-0573-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-015-0573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T23:33:16Z","timestamp":1717803196000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-015-0573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,22]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1007\/s11920-015-0573-1","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,22]]},"assertion":[{"value":"22 March 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35"}}